Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 39,333 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

39,333 Papers indexed
1,440 Papers AI scored
39,333 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

39333 results
B
AI -
Standard 76.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 76.1; sample size: 80.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 76.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 36.1; sample size: 60.0; recency: 100.0; abstract quality: 100.0.

B
A survival analysis of paediatric acute lymphoblastic leukaemia patients at the Moroccan University Hospital Centre of Rabat.
PMID 41561546 Published: 2025-09-15 Ingested: 2026-08-02 12:03 AM Ecancermedicalscience
AI -
Standard 76.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 56.1; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat.
PMID 40830697 Published: 2025-08-19 Ingested: 2026-08-02 12:04 AM Therapeutic innovation & regulatory science
AI -
Standard 76.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 46.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

B
TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.
PMID 40023593 Published: 2024-12-09 Ingested: 2026-08-02 12:03 AM The Journal of pharmacology and experimental therapeutics
AI -
Standard 76.72
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 66.1; sample size: 70.0; recency: 90.0; abstract quality: 85.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 76.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI -
Standard 76.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 23.5; sample size: 20.0; recency: 100.0; abstract quality: 100.0.

B
AI-powered segmentation and prognosis with missing MRI in pediatric brain tumors.
PMID 41530498 Published: 2026-01-13 Ingested: 2026-08-02 12:06 AM NPJ precision oncology
AI -
Standard 76.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 16.0; sample size: 80.0; recency: 100.0; abstract quality: 85.0.

B
Nursing Approach and Interventions to Prevent Nutritional Deficiencies in Paediatric Oncology: a Scoping Review.
PMID 41457741 Published: 2026-02-01 Ingested: 2026-08-02 12:06 AM International journal of nursing practice
AI -
Standard 76.7
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 76.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 43.5; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 324 of 3278
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic